Synergistic Pharmaceutical Compositions with Integrated Technologies
Legal Citation
Summary of the Inventive Concept
This inventive concept integrates the original pharmaceutical composition with advanced technologies, such as AI, IoT, blockchain, and novel materials, to create a more powerful and personalized system for pharmaceutical formulation, monitoring, and prediction.
Background and Problem Solved
The original patent relates to pharmaceutical compositions comprising an antibody, glycine, acetate buffer, and polysorbate 80. However, it has limitations in terms of stability, formulation, and personalization. The new inventive concept addresses these limitations by incorporating advanced technologies to enhance stability, optimize formulation, and provide personalized medicine.
Detailed Description of the Inventive Concept
The new inventive concept consists of synergistic combinations of the original pharmaceutical composition with advanced technologies. For instance, the system for monitoring and predicting pharmaceutical composition stability uses a blockchain-based database and an AI-powered algorithm to analyze stability data and predict potential instability. The method for optimizing pharmaceutical composition formulation employs an IoT-enabled sensor to monitor pH levels and adjust them in real-time to ensure stability. The pharmaceutical composition comprising a novel material with enhanced stability properties and a polysorbate 80 and acetate buffer system offers improved stability. The system for personalized medicine uses AI-powered algorithms to analyze patient-specific data and recommend personalized composition formulations. The method for predicting pharmaceutical composition stability using machine learning trains a model on a dataset of stability data to predict stability of new compositions.
Novelty and Inventive Step
The new claims introduce novel and non-obvious combinations of advanced technologies with the original pharmaceutical composition, providing a synergistic effect that enhances stability, optimizes formulation, and enables personalized medicine. The inventive step lies in the integration of these technologies to create a more powerful and effective system.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of other advanced technologies, such as quantum computing or nanotechnology, to further enhance the system's capabilities. Variations of the system could be designed for specific pharmaceutical applications, such as vaccine development or gene therapy.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of personalized medicine, pharmaceutical formulation, and stability monitoring. The target market includes pharmaceutical companies, research institutions, and healthcare providers seeking to improve the development and delivery of pharmaceutical products.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/39591 |
| A | A61 | A61K47/12 |
| A | A61 | A61K47/183 |
| A | A61 | A61K47/26 |
| C | C07 | C07K16/244 |
| C | C07 | C07K2317/76 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically antibody formulation and composition design, involving protein therapeutics, buffer systems, and advanced pharmaceutical technologies
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in pharmaceutical sciences, biotechnology, or chemical engineering, possessing expertise in protein stability, formulation techniques, and emerging technologies for drug development
Obviousness Rationale
A person of ordinary skill would recognize that integrating advanced monitoring and predictive technologies into pharmaceutical composition development represents a natural progression of existing pharmaceutical research methodologies. The PTD's proposed AI, blockchain, and IoT technologies are well-established in adjacent technical domains and would be considered straightforward extensions of existing pharmaceutical research and development practices. The core pharmaceutical composition remains fundamentally consistent with the source patent, with technological augmentations representing incremental improvements rather than radical innovations.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,625 |
|---|---|
| Title | Pharmaceutical compositions |
| Assignee(s) | UCB BIOPHARMA SRL |